$TIVC
Tivic Health Systems, Inc.

2022 Q1 Form 10-Q Financial Statement

#000141057822001666 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $428.0K $323.0K
YoY Change 32.51% 169.17%
Cost Of Revenue $358.0K $301.0K
YoY Change 18.94% 88.13%
Gross Profit $70.00K $22.00K
YoY Change 218.18% -173.33%
Gross Profit Margin 16.36% 6.81%
Selling, General & Admin $1.910M $881.0K
YoY Change 116.8% 17.47%
% of Gross Profit 2728.57% 4004.55%
Research & Development $401.0K $198.0K
YoY Change 102.53% -13.91%
% of Gross Profit 572.86% 900.0%
Depreciation & Amortization $2.000K $2.000K
YoY Change 0.0%
% of Gross Profit 2.86% 9.09%
Operating Expenses $2.311M $1.079M
YoY Change 114.18% 11.24%
Operating Profit -$2.241M -$1.057M
YoY Change 112.02% 5.7%
Interest Expense $0.00 $274.0K
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $1.000K -$299.0K
YoY Change -100.33%
Pretax Income -$2.240M -$1.356M
YoY Change 65.19% 35.6%
Income Tax
% Of Pretax Income
Net Earnings -$2.240M -$1.356M
YoY Change 65.19% 35.6%
Net Earnings / Revenue -523.36% -419.81%
Basic Earnings Per Share -$0.23 -$0.58
Diluted Earnings Per Share -$0.23 -$0.58
COMMON SHARES
Basic Shares Outstanding 9.715M 2.334M
Diluted Shares Outstanding 9.715M 2.334M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.80M $600.0K
YoY Change 1700.17%
Cash & Equivalents $10.80M $600.0K
Short-Term Investments
Other Short-Term Assets $633.0K $281.0K
YoY Change 125.27%
Inventory $447.0K $241.0K
Prepaid Expenses
Receivables $117.0K $79.00K
Other Receivables $0.00 $0.00
Total Short-Term Assets $12.00M $1.201M
YoY Change 899.0%
LONG-TERM ASSETS
Property, Plant & Equipment $16.00K $17.00K
YoY Change -5.88%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $33.00K $15.00K
YoY Change 120.0%
Total Long-Term Assets $696.0K $32.00K
YoY Change 2075.0%
TOTAL ASSETS
Total Short-Term Assets $12.00M $1.201M
Total Long-Term Assets $696.0K $32.00K
Total Assets $12.69M $1.233M
YoY Change 929.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $625.0K $664.0K
YoY Change -5.87%
Accrued Expenses $472.0K $257.0K
YoY Change 83.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $35.00K
YoY Change
Total Short-Term Liabilities $1.097M $1.830M
YoY Change -40.05%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.855M
YoY Change -100.0%
Other Long-Term Liabilities $504.0K
YoY Change
Total Long-Term Liabilities $504.0K $1.855M
YoY Change -72.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.097M $1.830M
Total Long-Term Liabilities $504.0K $1.855M
Total Liabilities $1.601M $3.685M
YoY Change -56.55%
SHAREHOLDERS EQUITY
Retained Earnings -$21.80M
YoY Change
Common Stock $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.09M -$2.517M
YoY Change
Total Liabilities & Shareholders Equity $12.69M $1.233M
YoY Change 929.52%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$2.240M -$1.356M
YoY Change 65.19% 35.6%
Depreciation, Depletion And Amortization $2.000K $2.000K
YoY Change 0.0%
Cash From Operating Activities -$2.168M -$665.0K
YoY Change 226.02% -48.45%
INVESTING ACTIVITIES
Capital Expenditures $6.000K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$6.000K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 221.0K
YoY Change -100.0% 2110.0%
NET CHANGE
Cash From Operating Activities -2.168M -665.0K
Cash From Investing Activities -6.000K 0.000
Cash From Financing Activities 0.000 221.0K
Net Change In Cash -2.174M -444.0K
YoY Change 389.64% -65.31%
FREE CASH FLOW
Cash From Operating Activities -$2.168M -$665.0K
Capital Expenditures $6.000K $0.00
Free Cash Flow -$2.174M -$665.0K
YoY Change 226.92% -48.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.23
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.58
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9715234
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2334479
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9715234
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9715234
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9715234
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9715234
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
647000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
687000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
33000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
49000
CY2022Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1000
CY2021Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
2000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1000
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-299000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-444000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
148000
CY2022Q1 us-gaap Inventory Gross
InventoryGross
447000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
429000
CY2022Q1 us-gaap Inventory Net
InventoryNet
447000
CY2021Q4 us-gaap Inventory Net
InventoryNet
429000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3Y9M29D
CY2022Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.060
CY2022Q1 us-gaap Liabilities
Liabilities
1601000
CY2021Q4 us-gaap Liabilities
Liabilities
1764000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001787740
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2022Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-32046
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9715234
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2334479
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.060
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
545000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11000
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Tivic Health Systems, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-4016391
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
25821 Industrial Blvd.,
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Hayward
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94545
CY2022Q1 dei City Area Code
CityAreaCode
888
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
276-6888
CY2022Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022Q1 dei Trading Symbol
TradingSymbol
TIVC
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9621484
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10801000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12975000
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
117000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
92000
CY2022Q1 us-gaap Inventory Net
InventoryNet
447000
CY2021Q4 us-gaap Inventory Net
InventoryNet
429000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
633000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
793000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
11998000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
14289000
CY2022Q1 us-gaap Assets
Assets
12694000
CY2021Q4 us-gaap Assets
Assets
15036000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
625000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
789000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
304000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
267000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
168000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
163000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1097000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1219000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
504000
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9715234
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9715234
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32878000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32817000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21786000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-19546000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11093000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
13272000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
12694000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15036000
CY2022Q1 us-gaap Revenues
Revenues
428000
CY2021Q1 us-gaap Revenues
Revenues
323000
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
358000
CY2021Q1 us-gaap Cost Of Revenue
CostOfRevenue
301000
CY2022Q1 us-gaap Gross Profit
GrossProfit
70000
CY2021Q1 us-gaap Gross Profit
GrossProfit
22000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
401000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
198000
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
684000
CY2021Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
300000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1226000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
581000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
2311000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
1079000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2241000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1057000
CY2021Q1 us-gaap Interest Expense
InterestExpense
274000
CY2021Q1 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-27000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2240000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1356000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2240000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-1356000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2200000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21800000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-1177000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2021Q1 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
-10000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-1356000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-2517000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
13272000
CY2022Q1 us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
-61000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2240000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
11093000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2240000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-1356000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
61000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
10000
CY2022Q1 us-gaap Depreciation
Depreciation
2000
CY2021Q1 us-gaap Depreciation
Depreciation
2000
CY2021Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-27000
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
261000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
40000
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
5000
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
22000
CY2021Q1 us-gaap Inventory Write Down
InventoryWriteDown
-8000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
30000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
33000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
18000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-7000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-175000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
62000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-163000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
295000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
36000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
170000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-36000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2168000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-665000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6000
CY2021Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
11000
CY2021Q1 tivc Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
74000
CY2021Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
300000
CY2021Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
221000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2174000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12975000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1044000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10801000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
600000
CY2021Q1 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
130000
CY2022Q1 us-gaap Area Of Land
AreaOfLand
9091
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10800000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9715234
CY2022Q1 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Reclassifications</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Certain reclassifications have been made to the prior year’s condensed balance sheet, condensed statement of operations and condensed statement of cash flows to conform to the current year presentation.</p>
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate.</p>
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
10300000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
12800000
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
83000
CY2021Q4 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
82000
CY2022Q1 us-gaap Contract With Customer Refund Liability
ContractWithCustomerRefundLiability
19000
CY2021Q4 us-gaap Contract With Customer Refund Liability
ContractWithCustomerRefundLiability
16000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2022Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
320000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9715234
CY2022Q1 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2022Q1 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
317000
CY2021Q4 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
63000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
647000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
687000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
168000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
163000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
504000
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk and Other Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents and accounts receivable. Cash and cash equivalents include accounts held at one financial institution in the United States. At times, such deposits may be in excess of insured limits. Management believes that the financial institution is financially sound, and accordingly, minimal credit risk exists with respect to the financial institution. The Company has not experienced any losses on its deposits of cash and cash equivalents. As of March 31, 2022 and December 31, 2021, the Company had cash and cash equivalents balances exceeding FDIC insured limits by $10.6 million and $12.5 million respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of March 31, 2022, the Company had two customers whose accounts receivable balances each totaled more than 10% or more of the Company’s total accounts receivable (60% and 30%) compared with two such customers at December 31, 2021 (54% and 39%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended March 31, 2022, the Company had one customer who individually accounted for 10% or more of the Company’s total revenue (20%) compared with two customers for the three months ended March 31, 2021 (18% and 11%).</p>
CY2022Q1 us-gaap Cash Uninsured Amount
CashUninsuredAmount
10600000
CY2021Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
12500000
CY2022Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
10343000
CY2022Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
10343000
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
10343000
CY2022Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
10343000
CY2021Q1 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
12793000
CY2021Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
12793000
CY2021Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
12793000
CY2021Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
12793000
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
10300000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
12800000
CY2022Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
545000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
672000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
708000
CY2022Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3Y6M29D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
313193
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.69
CY2022Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
46000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
0.30
CY2022Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
401000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
281000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
50000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
5000
CY2021Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
6000
CY2022Q1 us-gaap Lease Cost
LeaseCost
55000
CY2021Q1 us-gaap Lease Cost
LeaseCost
6000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y2M19D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
288000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.69
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
74000
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
46000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
155000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
206000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
210000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
178000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
749000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
77000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
672000
CY2022Q1 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
93000
CY2022Q1 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">6.</b></span>Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when future expenditures are probable and such expenditures can be reasonably estimated. The Company recorded no liabilities for contingent matters as of March 31, 2022.</p>
CY2022Q1 us-gaap Loss Contingency Loss In Period
LossContingencyLossInPeriod
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
749261
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1050969
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.02
CY2022Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
272680
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
272680
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1050969
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
607219
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
749261
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
707250
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2072910
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1587149
CY2022Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
280000
CY2021Q4 tivc Warrants Or Rights Fair Value Assumptions Method Used
WarrantsOrRightsFairValueAssumptionsMethodUsed
Black-Scholes options valuation model
CY2021Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
328000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2021 tivc Percentage Of Number Of Shares Added Each Year
PercentageOfNumberOfSharesAddedEachYear
0.050
CY2021 tivc Percentage Of Number Of Shares Added Each Year
PercentageOfNumberOfSharesAddedEachYear
0.05
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
707250
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
607219
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.23
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.06
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M21D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1163000
CY2022Q1 tivc Shares Reserved For Issuance
SharesReservedForIssuance
485761
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
443750
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
443750
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.73
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.69
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
0.90
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M23D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
10000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.25
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
61000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
930000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y4M24D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed
Black-Scholes options valuation model
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.4986
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.5336
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0.99
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0238
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
0
CY2022Q1 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
61000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1323649
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3026585
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2240000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1356000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9715234
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2334479
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.23
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.58
CY2022Q1 us-gaap Related Party Costs
RelatedPartyCosts
5000

Files In Submission

Name View Source Status
0001410578-22-001666-index-headers.html Edgar Link pending
0001410578-22-001666-index.html Edgar Link pending
0001410578-22-001666.txt Edgar Link pending
0001410578-22-001666-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tivc-20220331.xsd Edgar Link pending
tivc-20220331x10q.htm Edgar Link pending
tivc-20220331x10q001.jpg Edgar Link pending
tivc-20220331x10q_htm.xml Edgar Link completed
tivc-20220331xex31d1.htm Edgar Link pending
tivc-20220331xex31d2.htm Edgar Link pending
tivc-20220331xex32d1.htm Edgar Link pending
tivc-20220331_cal.xml Edgar Link unprocessable
tivc-20220331_def.xml Edgar Link unprocessable
tivc-20220331_lab.xml Edgar Link unprocessable
tivc-20220331_pre.xml Edgar Link unprocessable